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In this study we investigate the clinical outcomes of 305 breast cancer (BC) patients, aged 55 years or younger, with long follow-up
and according to intrinsic subtypes. The cohort included 151 lymph node negative (LN−) and 154 lymph node positive (LN+)
patients. Luminal A tumors were mainly LN−, well differentiated, and of stage I; among them AR was an indicator of good
prognosis. Luminal B and HER2 positive nonluminal cancers showed higher tumor grade and nodal metastases as well as higher
proliferation status and stage. Among luminal tumors, those PR positive and vimentin negative showed a longer survival. HER2-
positive nonluminal andTNpatients showed a poorer outcome,withBC-specific deathmostly occurringwithin 5 and 10 years.Only
luminal tumor patients underwent BCdeath over 10 years.When patients were divided in to LN− and LN+nodifferences in survival
were observed in the luminal subgroups. LN− patients have good survival even after 20 years of follow-up (about 75%), while for
LN+ patients survival at 20 years (around 40%) was comparable to HER2-positive nonluminal and TN groups. In conclusion, in
our experience ER-positive breast tumors are better divided by classical clinical stage than molecular classification, and they need
longer clinical follow-up especially in cases with lymph node involvement.
1. Introduction
Breast carcinoma (BC) encompasses a heterogeneous group
of tumors with great variability both at the molecular and at
the morphological levels. Clinical outcome is also variable,
some tumors are completely cured and others can recur
even after more than 10 years from surgical treatment. Gene
expression profiling throughmicroarray technology has been
designed to improve molecular taxonomy as a tool for sup-
porting clinical management of patients [1–3]. According to
molecular classification, BCs were grouped into at least four
“intrinsic” subtypes: two ER-positive luminal-like subtypes
and two ER-negative subtypes, HER2 overexpressing (HER2
positive nonluminal) and triple negative (TN).These intrinsic
subtypes showed different prognosis and outcome [3, 4].
Luminal tumors, divided into A and B subtypes, include
more than two-thirds of all BCs [5], while HER2 positive
nonluminal and triple negative (TN) make up, respectively,
15–20% and 10–15% of breast tumors [6]. However, due to
the limitation ofmicroarray-basedmolecular classification in
clinical practice, immunohistochemical (IHC) classification
by the analysis of estrogen receptor (ER), progesteron recep-
tor (PR), human epidermal growth factor receptor-2 (HER2),
and Ki67 (with a cutoff of 14%) has been proposed and
has been shown to correlate with gene expression profiling
data [6–11]. Furthermore, the St. Gallen consensus 2011 has
strongly supported the clinicopathological determination of
ER, PR, HER2, and Ki-67 as useful for defining subtypes,
as well as providing treatment recommendations for BC
intrinsic subtypes [7].
In normal breast tissue, luminal epithelial cells of ducts
and lobules are characterized by the expression of low
molecularweight cytokeratinCK8,CK18, CK19, andCK7.The
outer layer includes more heterogeneous cells that express
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high molecular weight cytokeratin, such as CK5/6 and CK14,
as well as nonepithelial cell markers such as vimentin, alpha
smooth muscle actin, but they do not express ER and PR
[12]. During the cells cancer transformation process, the CK
expression profile is often retained [13]. Basal-like tumors are
considered as those expressing at least one marker typical of
myoepithelial/basal cells [12], and for this reason cytokeratins
can be used to confirm the molecular class of the tumor.
Nevertheless, molecular classification is still a workingmodel
since a consensus on the definition of subtypes and on stan-
dardization of methodologies has not yet been completely
reached [14, 15].
The present study was carried out on a cohort of patients
under the age of 55 years (associated with a long follow-up
period) and aimed to
(i) classify BC in intrinsic subtypes luminal A, luminal B
(HER2 negative and HER2 positive), HER2 positive
(nonluminal), and triple negative;
(ii) detect the association between intrinsic subtypes,
clinical-pathological features, and outcome;
(iii) investigate the difference between prognostic impacts
of luminal A and B subtypes with the same tumor
stage.
2. Patients and Methods
2.1. Description of the Patients’ Cohort. All patients were
resident in a province in the northern-east area of Italy.
Inclusion criteria were (i) diagnosis of BC at least 15 years
before the censoring date of the study (December 31 2008),
(ii) invasive BC of stage I–III, (iii) age at diagnosis 55 years or
younger, and (iv) availability of formalin-fixed and paraffin-
embedded (FFPE) tissues. Caseswith a secondprimary breast
cancer or other malignancies were excluded from the study.
From 380 women initially enrolled, 75 patients with in situ
BC were excluded. Accordingly, 305 patients represented the
final cohort for the study, of these 154 (50.4%) presented with
lymph node involvement (LN+) at diagnosis. FFPE tissues of
the primary tumor obtained by surgical treatment were used.
Clinical information was obtained from medical records.
Tumors were reviewed and histologically classified according
to the World Health Organization (WHO 2003) [16], graded
using Elston and Ellis grading system [17] and grouped into
stages according to TNM classification [18]. The patients’
cohort was followed for a maximum of 25 years through
the local Cancer Registry from diagnosis of BC to death or
until censoring date. This study was approved by the Ethical
Committee of the University of Trieste.
Fifteen patients (5%) were lost at follow-up during the
period of observation because of emigration. The mean
age at diagnosis was 47 years (range 26–55). No significant
differences in age at diagnosis were observed between the
LN− (46.8 y, range 32–55 y) and LN+ (47.0 y, range 26–55 y)
groups, but the frequency of patients under 35 years was
higher in LN+.
Patients were treated with mastectomy or breast-
conserving surgery. All patients submitted to conserving
surgery were treated with radiotherapy. All LN+ patients
were treated with adjuvant chemotherapy with CMF (cyclo-
phosphamide, methotrexate, and fluorouracil) or EC/ECF
(epirubicin, cyclophosphamide, and fluorouracil) regimens
according to standard protocols. ER-positive patients, both
LN− and LN+, were submitted to hormone therapy with
tamoxifen. No specific treatment with trastuzumab was
performed in HER2 positive patients, because this therapy
was not available at the time of diagnosis.
The median follow-up time was 16 years (range 0–25). In
detail it was 18 years (range 0–25) for the LN− group and 9
years (range 0–24) for the LN+ group (𝑃 = 0.000). In the LN−
group 49 women (33%) recurred, while in the LN+ group
98 patients (69%) did so. For 4 LN− patients (3%) and 11
LN+ ones (7%) no information about recurrences was given.
All clinical and pathological characteristics are reported in
Table 1.
2.2. Tissue Microarray. Each patient’s haematoxylin and
eosin (H&E) slides were reviewed by an expert pathologist
(R. Barbazza), who marked the representative tumor areas
to be analyzed. Tissue microarrays (TMAs) were constructed
by the use of the FFPE tissues of the entire cohort using
the Galileo TMA CK3500 (Integrated Systems Engineering,
Milano, Italy), as previously described [19]. Multiple tissue
cores were sampledwhen the tumor presentedwith histologi-
cal heterogeneous regions.One section from eachTMAblock
was stained with H&E to confirm the presence of carcinoma.
2.3. Immunohistochemical Staining. IHC staining was per-
formed following the standard procedures [20], accord-
ing to the manufacturers’ instructions for each MAb
used. Immunostaining was performed manually with the
Vectastain Universal Elite ABC kit (Vector Laboratories,
Burlingame, CA, USA) for ER, PR, CK8, CK5/6, and
vimentin. Ready-to-use antibodies for ER (CONFIRM anti-
Estrogen Receptor clone SP1; Ventana Medical System, Tuc-
son, AZ, USA), PR (CONFIRM anti-Progesterone Receptor
clone 1E2; Ventana), vimentin (CONFIRM anti-Vimentin
clone V9; Ventana), and CK5/6 (clone D5&16B4; diluted
1 : 100 Aczon Biotech, Monte San Pietro, Bologna, Italy) were
applied for 60 minutes after 20-minute antigen retrieval in
0.1MpH 8 Tris-Borate 1mM EDTA at high temperature, in
water bath. CK8 antibody (clone M20; Abcam, Cambridge,
UK) was used at 1 : 250 dilution with 60-minute incuba-
tion, after 20-minute antigen retrieval in 10mMpH6 Citrate
Buffer at high temperature in water bath. For visualization,
the DAB Substrate kit for Peroxidase (Vector Laboratories,
Burlingame, CA, USA) was used.
Immunostaining for Ki67 (clone MIB-1; 1 : 200 dilution,
DakoDenmark A/S, Glostrup, Denmark) and HER2 (clone
CB11; 1 : 300 dilution Thermo Scientific, Astmoor Runcorn,
Cheshire,UK)was performed in LabVisionAutostainer 480S
(Thermo Scientific) with the UltraVision LP Large Volume
Detection System HRP Polymer (Lab Vision Corporation,
Thermo Scientific) according to manufacturer’s instructions.
HER2 gene amplification in case of equivocal staining (2+)
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Table 1: Clinical-pathological parameters and immunohistochemistry results of the BC cohort (𝑁 = 305) and with respect to lymph node
involvement.
Features Entire cohort (305) n (%) LN− (151) n (%) LN+ (154) n (%) P
Mean age, years 46.9 46.8 47.0 0.2
(range) (26–55) (32–55) (26–55)
Age, years
≤35 21 (7) 4 (3) 17 (11) 0.004∗
>35 284 (93) 147 (97) 137 (89)
Histology
Ductal 250 (83) 117 (77) 136 (88)
0.001∗
Lobular 28 (9) 13 (9) 15 (10)
Medullary 6 (2) 6 (4) 0
Mucinous 7 (2) 4 (3) 3 (2)
Tubular 12 (4) 11 (7) 0
Grade
1 39 (13) 34 (22) 5 (3)
0.000∗2 145 (47) 86 (57) 59 (38)
3 121 (40) 31 (21) 90 (59)
Tumor size, cm
≤2 181 (60) 109 (72) 72 (48)
0.000∗2–5 106 (35) 39 (26) 67 (44)
≥5 15 (5) 3 (2) 12 (8)
Missing 3 0 3
Lymph nodes
1–3 lymph nodes 97 (63) 0 97 (63)
≥4 lymph nodes 56 (37) 0 56 (37)
Missing 1 0 1
Stage
I 107 (35) 107 (71) 0
II 125 (41) 42 (28) 83 (54)
III 72 (24) 2 (1) 70 (46)
Missing 1 0 1
Type of surgery
Mastectomy 221 88 133 0.001∗
Breast conservation 84 63 21
Recurrence
No 143 (49) 98 (67) 45 (31)
0.000∗Yes 147 (51) 49 (33) 98 (69)
Missing 15 4 11
BC specific death 128 (42) 39 (26) 89 (58)
0.000∗Living 143 (47) 99 (65) 44 (28)
Other cause death 16 (5) 7 (5) 9 (6)
Lost at FU 18 (6) 6 (4) 12 (8)
ER
Negative 63 (21) 25 (17) 38 (25) 0.08
Positive 242 (79) 126 (83) 116 (75)
PR
Negative 81 (27) 27 (18) 54 (35) 0.001∗
Positive 224 (73) 124 (82) 100 (65)
HER2
Negative 244 (80) 140 (93) 104 (67) 0.000∗
Positive 61 (20) 11 (7) 50 (33)
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Table 1: Continued.
Features Entire cohort (305) n (%) LN− (151) n (%) LN+ (154) n (%) P
Ki67
<14% 156 (51) 104 (69) 52 (34) 0.000∗
≥14% 149 (49) 47 (31) 102 (66)
CK8
Negative 29 (10) 11 (7) 18 (12) 0.3
Positive 276 (90) 140 (93) 136 (88)
CK5/6
Negative 235 (77) 109 (72) 126 (82) 0.04∗
Positive 70 (23) 42 (28) 28 (18)
Vimentin
Negative 196 (64) 106 (70) 90 (58) 0.03∗
Positive 109 (36) 45 (30) 64 (42)
AR
Negative 80 (37) 29 (30) 51 (43) 0.04∗
Positive 136 (63) 69 (70) 67 (57)
ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor-2, CK8: cytokeratin 8, CK5/6: cytokeratin 5/6, AR: androgen
receptor. ∗Statistically significant data.
was assessed by SISH assays using the ultra View SISH DNP
Detection Kit (Ventana) in Benchmark XT automated slide
strainer instrument, as previously described [21].
IHC for androgen receptor (AR) was performed with
mouse monoclonal antibody (AR441, DakoDenmark A/S,
Glostrup, Denmark) as previously described [22].
Positive and negative control slides were used in each IHC
assay.
2.4. Evaluation of Immunohistochemistry and Definition of
Intrinsic Subtypes. Immunostaining was quantitatively eval-
uated by two different observers in a blinded fashion (DP, RB)
using light microscopy and counting the positive cells across
three high power fields (HPF at 40x magnification), each
containing about one hundred cells. Tumors were considered
as positive for ER and PR if more than 10% of tumor nuclei
were stained independently of staining intensity [10, 23],
because at the time of diagnosis this was the cutoff used to
submit patients to Tamoxifen treatment. This is a deviation
from the St. Gallen consensus and ASCO/CAP guidelines,
which defined those cases presenting with more than 1% of
tumor cells independently of staining intensity as hormonal
receptor positive [7, 24]. The cutoff for CK8 and CK5/6
positivity was 10% of cells as well. Tumors were considered as
positive for vimentin and AR when more than 1% of tumor
cells were stained [22, 25].
HER2 overexpression was scored according to ASCO
guideline [26]. Our patients had a diagnosis of BC between
1983 and 1993 andno specific treatmentwith trastuzumabwas
performed in those years. Since we had no information about
the scoring of HER2 at the time of diagnosis, we adopted
the current method. For evaluation of Ki67 immunostaining,
the positively stained cancer cells were counted manually
across three high power fields (HPF). The mean value was
used for Ki67 score. Ki67 threshold of 14% of nuclear staining
of cancer cells was used to discriminate low proliferation
index (<14%) and high proliferation index (≥14%) [5, 7].
The tumors were then classified into the four main intrinsic
subtypes according to the staining profile of the antigen
markers: ER, PR, HER2, and Ki67 [5, 7, 11, 27]. CK8, CK5/6,
vimentin, and AR were investigated in the entire case study.
In detail, cases that were ER positive and/or PR positive,
HER2 negative, and low Ki67 were classified as luminal A;
cases that were either (i) ER positive and/or PR positive,
HER2 negative, and high Ki67 (luminal B HER2 negative) or
(ii) ER positive and/or PR positive, HER2 positive (luminal
B HER2 positive) were classified as Luminal B; tumors ER
negative, PR negative, and HER2 positive were defined as
HER2 positive; cases ER negative, PR negative, and HER2
negative, were classified as triple negative (TN), a surrogate
for subtybe [6]. If the tumors exhibited markers staining that
did not meet the abovementioned panel criteria, they were
defined as “unclassified.”
2.5. Statistical Analysis. Associations between clinical-patho-
logical data, lymph node involvement, and intrinsic subtypes
were tested for significance using the Chi-square test for
categorical variables. For continuous variables the parametric
Student’s t-test, the one-way ANOVA test, or the Kruskal-
Wallis test was used. BC specific survival was defined as
the time from surgery to breast cancer specific death or
end of follow-up, whichever came first. To estimate the
joint effects of the analyzed covariates on patients’ survival,
the data were analyzed by fitting the Cox proportional
hazard regression model. Cox proportional hazard analysis
included pathological variables (age at diagnosis, histological
type, tumor size, lymph nodes status, and tumor grade)
and intrinsic subtypes as covariates. The log-rank test was
used to check the dependence of patients’ survival on single
variables or on combinations of variables. All𝑃 values are two
sided with values <0.05 regarded as statistically significant. 𝑃
values between 0.05 and 0.07were considered as “borderline.”
Disease Markers 599
0.00
0.25
0.50
0.75
1.00
Su
rv
iv
al
 p
ro
ba
bi
lit
y
0 5 10 15 20 25
Follow-up (years)
Survival by molecular classes
(P = 0.0003)
(a)
0.00
0.25
0.50
0.75
1.00
Su
rv
iv
al
 p
ro
ba
bi
lit
y
0 5 10 15 20 25
Follow-up (years)
(P = 0.09)
Survival by molecular classes in LN−
(b)
0.00
0.25
0.50
0.75
1.00
Su
rv
iv
al
 p
ro
ba
bi
lit
y
0 5 10 15 20 25
Follow-up (years)
Luminal A Luminal B
Triple negativeHER-2+
(P = 0.2)
Survival by molecular classes in LN+
(c)
Figure 1: Kaplan-Meier survival curves with respect to molecular classes in (a) the cohort of BC patients (𝑁 = 304, 128 BC specific deaths),
(b) lymph node negative tumors (𝑁 = 150, 39 BC specific deaths), and (c) classes in lymph node positive tumors (𝑁 = 154, 89 BC specific
deaths).
Statistical analyses were performed with the Stata/SE 12
package (Stata, College Station, TX, USA).
3. Results
3.1. Survival according to Intrinsic Subtypes. The BC specific
survival curves per intrinsic subtypes for the entire cohort are
shown in Figure 1. A significantly better BC specific survival
was recorded for luminal A tumors and a worse outcome
was observed for HER2 positive nonluminal subtype (𝑃 =
0.0003). In detail, significant differences were found between
luminal A and luminal B (𝑃 = 0.009), luminal A and HER2
positive (nonluminal) (𝑃 = 0.0003), luminal A and TN
(𝑃 = 0.01), and luminal B and HER2 positive nonluminal
(𝑃 = 0.04). Therefore no significant differences between
HER2 positive nonluminal and TN (𝑃 = 0.3), and luminal
B and TN (𝑃 = 0.5) were detected.
Considering luminal A and B together, PR positive
tumors showed a significantly better outcome in comparison
with negative ones (𝑃 = 0.02), as shown in Figure 2.
Vimentin-positive luminal tumors had shorter survival com-
pared to negative ones (𝑃 = 0.03) (Figure 3). HER2 (𝑃 = 0.5)
and CK5/6 (𝑃 = 0.9) expression did not seem to influence BC
specific survival among luminal tumors. Moreover, luminal
A tumors, but not luminal B, with AR-positive expression
showed significant longer survival with respect to negative
ones (𝑃 = 0.01), as shown in Figure 4.
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Figure 2: Kaplan-Meier survival curves according to PR expression
in luminal tumors (𝑁 = 240, 93 BC specific deaths).
Cox multivariate analysis run for pathological variables
and for themolecular subtypes revealed that histological type,
tumor grade, lymph node involvement, and luminal tumors
(A and B) showed an independent influence on BC specific
survival, as reported in Table 2.
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Figure 3: Kaplan-Meier survival curves according to vimentin
expression in luminal tumors (𝑁 = 240, 93 BC specific deaths).
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Figure 4: Kaplan-Meier survival curves according to AR in luminal
A tumors (𝑁 = 92, 32 BC specific deaths).
Table 2: Cox multivariate regression analysis for breast cancer
survival in the entire cohort (𝑁 = 302).
Risk factors Hazard ratio 95% CI∗ P
Age at diagnosis 1.0 0.9-1.0 0.4
Histologic type 0.8 0.6–1.0 0.04∗
Grade 1.4 1.0–1.9 0.05
Tumor size 1.2 0.9–1.7 0.2
Lymph node 2.4 1.5–3.7 0.000∗
Luminal A 0.2 0.1–0.9 0.04∗
Luminal B 0.2 0.1–0.8 0.03∗
HER2 positive nonluminal 0.3 0.1–1.4 0.1
Triple negative 0.4 1.0–1.6 0.2
∗Statistically significant data.
By comparing luminal patients who hadBC specific death
within 10 years (68 out of 93) with those who died from
BC after 10 years (25 out of 93), tumors with higher Ki67
(𝑃 = 0.02) and positive to vimentin (𝑃 = 0.02) tend to cause
more frequently “late” BC specific death.
3.2. Clinical Pathological Features of Intrinsic Subtypes. Lumi-
nal A was the most frequent molecular subtype with 140
patients (46%), followed by luminal Bwith 102 women (34%),
38 TN (12%), and 24 HER2 positive (nonluminal) (8%). One
case failed to be classified in one of the molecular subtypes,
because it exhibited staining for PR, CK8, and high Ki67, but
not for ER, HER2, and CK5/6.
Clinical and pathological details stratified per intrinsic
subtypes are shown in Table 3.
Significant associations between intrinsic subtypes and
age at diagnosis (cutoff 35 years) (𝑃 = 0.03), histological
type (𝑃 = 0.001), tumor grade (𝑃 = 0.000), lymph node
involvement (𝑃 = 0.000), tumor stage (𝑃 = 0.000), and
presence of later recurrences (𝑃 = 0.006) were found.
Patients under 35 years at diagnosis more frequently fell into
luminal B and HER2 positive (nonluminal) subtypes. Tumor
size distribution did not show any difference in the intrinsic
subtypes, but it was significantly higher in LN+ group (𝑃 =
0.000).
An important association between molecular classifica-
tion and LN involvement was detected (𝑃 = 0.000). Most
luminal A tumors were of stage I at diagnosis, while most
luminal B tumors were of stage II and nearly half of HER2
positive (nonluminal) of stage III. TN tumors were equally
distributed in the three stages. In the entire case study,
luminal A subtype showed the lowest percentage of recur-
rences, while more than 75% of HER2 positive nonluminal
tumors relapsed. Luminal B andTNpatients showed a similar
intermediate percentage of recurrences.
Vimentin prevailed in triple negative subgroup (75% of
positive tumors) as compared to other classes (𝑃 = 0.000).
AR was evaluated in 216 tumors (tissue cores of 89
patients were not analyzable on TMAs), of which 136 were
positive, as reported in Table 1. AR-positive staining was
significantly associated with LN− tumors (𝑃 = 0.04), low-
grade tumors (𝑃 = 0.001), and tumor stage I-II (𝑃 = 0.04).
All medullary tumors were AR negative, whereas 75% of
mucinous and 88% of tubular carcinomas were AR positive
(𝑃 = 0.02). No significant association between AR positivity
and tumor size was detected; however, the log-rank test
revealed a significantly better outcome for patients showing
positive AR expression, in comparison to negative ones, on
the whole cohort (𝑃 = 0.03). Moreover, AR positivity was
significantly associated with ER-positive (𝑃 = 0.000) and PR-
positive (𝑃 = 0.000) tumors.
When we analyzed LN− and LN+ groups separately,
we observed similar frequency of recurrences for luminal
subtypes: 33% and 26% of recurrences in luminal A and
luminal B in LN−; 64% and 67% for luminal A and B in
LN+, respectively (𝑃 = 0.6 and 𝑃 = 0.8). The result was
also confirmed for cancer specific deaths: frequencies were
comparable in luminal A and B subgroups when divided per
lymph node involvement (𝑃 = 0.9 for both). Survival rates
of luminal A and B patients were 0.75 at 25 years for both in
lymph LN− and in LN+, they were 0.42 for luminal A and
0.34 for luminal B (at 25 years).
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Table 3: General clinical-pathological parameters and immunohistochemistry results of breast tumors according to molecular classification
(𝑁 = 304).
Features Luminal A (140) n (%) Luminal B (102) n (%) HER2 (24) n (%) Triple negative (38) n (%) P
Age at diagnosis, years 47.4 46.6 45.9 46.5 0.7
(range) (30–55) (30–55) (28–55) (26–55)
Age, years
≤35 4 (3) 10 (10) 4 (17) 3 (8) 0.04∗
>35 136 (97) 92 (90) 20 (83) 35 (92)
Histology
Ductal 110 (79) 89 (87) 23 (96) 30 (79)
0.002∗
Lobular 16 (11) 10 (10) 1 (4) 1 (3)
Medullary 0 0 0 6 (16)
Mucinous 3 (2) 3 (3) 0 1 (3)
Tubular 11 (8) 0 0 0
Grade
1 34 (25) 5 (4) 0 0
0.000∗2 77 (55) 49 (48) 9 (37) 9 (24)
3 29 (20) 48 (48) 15 (63) 297 (76)
Tumor size, cm
≤2 95 (68) 50 (49) 12 (50) 23 (62)
0.12–5 39 (28) 44 (43) 11 (46) 12 (32)
≥5 5 (4) 7 (7) 1 (4) 2 (5)
Missing 1 1 0 1
Lymph node involvement
No 98 (70) 28 (27) 5 (21) 19 (50) 0.000∗
Yes 42 (30) 74 (73) 19 (79) 19 (50)
Lymph nodes
1–3 28 (67) 51 (69) 10 (53) 8 (44)
0.1
≥4 14 (33) 23 (31) 9 (47) 10 (56)
Missing 0 0 0 1
Stage
I 71 (51) 17 (16) 4 (16) 14 (38)
0.000∗II 48 (34) 55 (54) 9 (38) 13 (35)
III 21 (15) 30 (30) 11 (46) 10 (27)
Missing 0 0 0 1
Recurrence
No 78 (58) 43 (45) 5 (23) 16 (42)
0.02∗Yes 56 (42) 53 (55) 17 (77) 21 (55)
Missing 6 6 2 1
Status
BC specific death 45 (32) 48 (47) 14 (58) 21 (55)
ER
Negative 0 0 24 (100) 38 (100)
Positive 140 (100) 102 (100) 0 0
PR
Negative 6 (4) 13 (13) 24 (100) 38 (100)
Positive 134 (96) 89 (87) 0 0
HER2
Negative 140 (100) 65 (64) 0 38 (100)
Positive 0 37 (36) 24 (100) 0
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Table 3: Continued.
Features Luminal A (140) n (%) Luminal B (102) n (%) HER2 (24) n (%) Triple negative (38) n (%) P
Ki67
<14% 140 (100) 6 (6) 4 (17) 6 (16)
≥14% 0 96 (94) 20 (83) 32 (84)
CK8
Negative 0 0 5 (21) 24 (63)
Positive 140 (100) 102 (100) 19 (79) 14 (37)
CK5/6
Negative 125 (89) 89 (87) 19 (79) 2 (5)
Positive 15 (11) 13 (13) 5 (21) 36 (95)
Vimentin
Negative 107 (76) 65 (64) 14 (58) 10 (26) 0.000∗
Positive 33 (24) 37 (36) 10 (42) 28 (74)
AR
Negative 19 (21) 20 (26) 14 (70) 26 (100) 0.000∗
Positive 73 (79) 57 (74) 6 (30) 0
ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor, CK8: cytokeratin 8, CK5/6: cytokeratin 5/6, AR: androgen
receptor. ∗Statistically significant data.
Table 4: Metastasis sites and local recurrence in accordance with BC molecular subtypes.
Intrinsic subtypes (n) Localn (%)
Bone
n (%)
Liver
n (%)
Lung and pleura
n (%)
Brain
n (%)
Endocrinea
n (%)
Distant LNb
n (%)
Otherc
n (%)
Luminal A (140) 22 (16) 23 (16) 28 (21) 25 (18) 2 (1) 4 (3) 4 (3) 5 (4)
Luminal B (102) 13 (13) 29 (28) 27 (26) 20 (20) 8 (8) 4 (4) 2 (2) 6 (6)
HER2 positive (24) 7 (29) 3 (12) 7 (29) 6 (25) 4 (17) 1 (4) 1 (4) 1 (4)
TN (38) 5 (13) 12 (32) 13 (34) 14 (37) 4 (11) 1 (3) 1 (3) 1 (3)
aEndocrine sites include thyroid, ovary, and kidney. bDistant lymphnodes are considered the nodes that donot belong to the axilla, including the supraclavicular
lymph nodes. cOther sites comprise peritoneum and pericardium.
3.3. Pattern of Local and Distant Metastases. The pattern of
metastatic sites was reported in Table 4. Organ distribution of
metastasis among intrinsic subtypes was almost similar, but
for bone and brain. HER2 positive (nonluminal) type exhib-
ited a lower rate (12%) of bone metastasis in comparison to
other subtypes (𝑃 = 0.03). In particular, for bone involvement
significant differences were found between HER2 positive
(nonluminal) and luminal B (𝑃 = 0.01) and TN (𝑃 =
0.04). A higher rate of brain metastases was found in both
HER2 positive (nonluminal) (17%) and TN (11%) (𝑃 = 0.03).
In detail, a significant difference for brain metastases was
observed between HER2 positive (nonluminal) and luminal
A (𝑃 = 0.02) and TN and luminal A (𝑃 = 0.04).
4. Discussion
Current BC clinical management is based on the assessment
of traditional clinical and pathological factors and some
molecular markers, such as ER, PR HER2, and Ki67. More
recently, the 2011 St Gallen International Breast Cancer
Conference [7] suggested using immunohistochemistry for
molecular subtyping [5, 7, 8, 14] with the analysis of ER, PR,
HER2, and Ki67 to subdivide patients into luminal A and B,
HER2 positive nonluminal, and triple negative.
In this study we investigated the prognostic role of BC
molecular classification in a cohort of 305 BC patients aged
55 years or younger at diagnosis, to obtain a long follow-
up (mean follow-up: 14 years). To this purpose we used the
panel of four biomarkers for molecular subgrouping by IHC,
ER, PR, HER2, Ki67, [5, 6, 28, 29], plus CK8, CK5/6 (to
confirm the luminal and basal-like types), vimentin, and AR
as additional markers.
The distribution of intrinsic subtypes obtained by IHC in
our patients’ cohort was similar to other previous studies [11,
27, 30]: luminal tumors were the most represented subtype
with 80% of cases, followed by TN cancers (12%) and HER2
positive nonluminal (8%). In agreement with other studies, a
significant association between clinical-pathological features
and molecular subtypes was observed [3, 6, 8, 31]. In particu-
lar, most low-grade tumors that displayed features of luminal
A, conversely poorly differentiated were mainly luminal B
and HER2 positive nonluminal subtypes (𝑃 = 0.000). In TN
subtype the rate of G3 tumors was significantly higher, as
already reported [6, 32]. RegardingBChistology, pure tubular
and mucinous types, related to a favorable prognosis [16],
were luminal tumors, as well as lobular ones. HER2 positive
nonluminal and TN molecular classes tumors were mostly
of the ductal histological type, as already reported [29, 33].
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Medullary carcinomas, whose histological type is rare, were
classified as triple negative tumors [29, 31].
Regarding ER-positive tumors, luminal A type was
mainly represented in LN−, while luminal B was more
common in the LN+ group, and this is the main clinical
difference between the two groups. Luminal B and HER2
positive nonluminal frequently presented at diagnosis with
lymph node involvement, in agreement with Wiechmann
et al. [30]. Conversely, TN tumors were equally distributed
between LN− and LN+ groups, showing that its progno-
sis is mainly related to their intrinsic biological behavior
[34]. Triple negative, as well as HER2 positive nonluminal,
subtypes presented with higher rate of brain metastasis in
comparison with luminal A tumors, in agreement with other
reports [11, 12, 34].
A few luminal A tumors exhibited cancer specific death,
while the HER2 positive nonluminal subtype presented with
the highest rate of relapses, as already reported [11]. Luminal
B and TN showed a similar intermediate frequency of
recurrences, also reflected by specific survival (Figure 1(a)).
However, if we consider luminal A and B by lymph node
involvement, they exhibited in the two groups similar fre-
quencies of recurrences. These data are also confirmed by
BC specific survival as shown in Figures 1(b) and 1(c). This
finding is related to the fact that the cutoffs to define luminal
A and luminal B cancer are arbitrarily set [14], and by IHC
they differ for the rate of Ki67 andHER2 overexpression, both
characteristic of higher aggressiveness. Our results point out
that the recurrence rate and cancer specific deaths are highly
dependent on the status of axillary lymph nodes rather than
on splitting between luminal A and B subtypes. In agreement
with us, recent studies have called into question the very
existence of this subclassification and have suggested that ER-
positive cancers form a continuum rather than segregate into
distinct subtypes [14]. However, we recognize as a possible
limitation that in this study no luminal B HER 2 positive
subclassification has been performed, because of the limited
number of cases.
In our cohort, luminal B tumors were often negative to
PR (𝑃 = 0.03), but positive to vimentin expression (𝑃 =
0.003) with respect to luminal A. Other authors have already
reported on vimentin expression in luminal epithelium of the
breast and on its positive correlation with ER in BC tumors
[25, 35].
Furthermore, vimentin expression and higher Ki67 were
significantly associated with worse survival in the subgroup
of luminal patients who died from BC after 10 years. This
suggests that vimentin and Ki67 could represent long-term
unfavorable prognostic markers in ER-positive tumors. We
also observed that most ER-positive tumors were positive to
AR, which seem to be a marker of good prognosis, as already
reported [22], especially in early stages of luminal tumors.
Of note in the period of diagnosis of our cohort of patients,
LN− patients were not treated with cytotoxic chemotherapy,
according to regimens of those years.
To our knowledge this is the first study investigating
BC specific survival associated with intrinsic subtypes in a
population with up to 25 years of follow-up. As expected, we
observed that BC specific survival analysis identified twowell
separated groups of tumors: ER-positive and ER-negative.
ER-positive LN negative cancers have the best outcome, and
ER-positive LN positive cases showed an intermediate overall
survival, while TN and HER2 positive nonluminal types
showed the shortest survival, as already reported [2, 3, 11, 14,
33]. HER2 positive nonluminal and TN subtypes displayed
a very aggressive outcome with early BC specific death
within 5 and 10 years, respectively. However we recognize
that a possible limitation of the study is the low number of
patients in the HER2 positive non luminal (24) and TN (38)
subtypes.
Cox proportional hazard model confirmed an inde-
pendent and favorable influence on BC survival for lumi-
nal tumors (ER-positive), together with the pathological
variables, histological type, tumor grade, and lymph node
involvement.
Taken together, our results stress that, in our experience,
luminal A and luminal B belong to a unique clinical group of
ER-positive tumors, and their clinical differences are mainly
related to a different tumor stage at diagnosis. We also
observed that the most important predictor of prognosis ER-
positive tumors was still the lymph node involvement, which
is still reported as one of the most relevant prognostic factors
[36].
Although patients with luminal tumors showed signifi-
cantly longer BC survival, they frequently undergo over 10-
year long-term BC deaths [11]. In our case study 10% of
luminal BC patients died from BC after 10 years of follow-
up. It is possible to hypothesize that ER-positive tumors
with high Ki67 and vimentin positivity harbor some specific
biological properties that slow down progression for a very
long time and may postpone BC specific death even for
20 years.
Thereforewe strongly believe thatmonitoring and follow-
up program should be different according to cancer subtypes,
and, in case of luminal tumors, prolonged controls are
recommended because of possible relapses.
5. Conclusion
Luminal tumors (ER positive) showed longer survival and
better prognosis with respect to ER-negative ones, as it is
widely accepted. In addition, AR resulted in a significant
prognosticmarker among luminal A patients. Fromour long-
term survival study ER-positive tumors are confirmed to
be a single clinical group, diagnosed in different periods
of cancer progression. The prognosis is good for LN− ER-
positive patients independently of any furthermolecular class
and very severe for LN+. In this group, general survival after
20 years is very similar to HER2 positive nonluminal tumors
after 5 years and to TN after 10 years.
Finally, together with Ki67 the use of PR and vimentin as
prognostic markers could help to better stratify patients with
ER-positive tumors with respect to clinical outcome.
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